Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Boom – page 17

2 148 clinical trials in Boom, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Boom at a glance
2 148
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

2 148 trials in Boom

Open in trial search

Phase 1/2 Study of VS-7375 with Drug Combination in Patients with Advanced KRAS G12D‑Mutated Solid Tumors

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Verastem Inc.

Obesity

Recruiting

Semaglutide for weight management in adults with obesity and binge‑eating: a study to identify who benefits

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Semaglutide
  • Sponsor:UZ Leuven

Rituximab and venetoclax treatment for 6 vs 26 cycles in patients with relapsed or refractory chronic lymphocytic leukemia

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Venetoclax
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Evaluation of NXT007 versus Emicizumab Prophylaxis in Patients with Hemophilia A

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Emicizumab
  • Sponsor:F. Hoffmann-La Roche AG

Myelofibrosis+1

Recruiting

Study of pelabresib (DAK539) plus ruxolitinib versus placebo plus ruxolitinib in adult patients with myelofibrosis who are JAK‑inhibitor‑naive

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ruxolitinib
  • Sponsor:Novartis Pharma AG

Long‑Term Safety and Efficacy of RO7790121 in Adults with Moderate to Severe Rheumatoid Arthritis: Extension Study

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:RO7790121
  • Sponsor:F. Hoffmann-La Roche AG

Crohn's disease

Recruiting

A Phase 3b Study of Guselkumab Compared with Risankizumab in Adults with Moderately to Severely Active Crohn’s Disease

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

Asthma

Recruiting

Efficacy and safety of GB-0895 as adjunctive therapy in adults and adolescents with severe uncontrolled asthma (randomized, placebo‑controlled)

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:GB-0895
  • Sponsor:Generate Biomedicines Inc.

Phase 3 Randomized Double‑Blind Placebo‑Controlled Study of Intravenous sgt-003 in Ambulatory Male Patients with Duchenne Muscular Dystrophy

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:SGT-003
  • Sponsor:Solid Biosciences Inc.

Neoplasm

Recruiting

Safety and Efficacy of Ifinatamab Deruxtecan in Pediatric Patients Under 18 With Relapsed or Refractory Solid Tumors

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Ifinatamab Deruxtecan
  • Sponsor:Merck Sharp & Dohme LLC

Pumitamig Versus Durvalumab in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Without Progression After Chemoradiation

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

EIK1001, Pembrolizumab, and Chemotherapy for Stage 4 Non-Small Cell Lung Cancer in Patients with Stage 4 Non-Small Cell Lung Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Eikon Therapeutics Inc.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.